 | • レポートコード：QYR9ST03695 • 出版社/出版日：QYResearch / 2019年9月2日 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、90ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療・製薬 |
| Single User | ￥577,200 (USD3,900) | ▷ お問い合わせ |
| Enterprise License | ￥1,154,400 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| ※当調査レポートでは、非アルコール性脂肪性肝疾患治療の世界市場について調査・分析し、非アルコール性脂肪性肝疾患治療の世界市場規模、市場動向、主要企業別マーケットシェア、主要地域別市場規模、企業プロフィールなどの情報をまとめました。また、セグメント分析では、種類別（酸化防止剤、チアゾリジンジオン、ビグアナイド、脂質低下剤、FXR受容体アゴニスト、その他）、用途別（病院薬局、小売薬局、ドラッグストア、オンライン薬局、その他）、地域別（北米、ヨーロッパ、中国、日本国内、東南アジア、インド、中南米）に区分して市場規模を算出しました。 ・レポートの概要 ・世界の非アルコール性脂肪性肝疾患治療市場動向 ・主要企業別マーケットシェア ・非アルコール性脂肪性肝疾患治療の種類別市場規模2014-2019 （酸化防止剤、チアゾリジンジオン、ビグアナイド、脂質低下剤、FXR受容体アゴニスト、その他） ・非アルコール性脂肪性肝疾患治療の用途別市場規模2014-2019 （病院薬局、小売薬局、ドラッグストア、オンライン薬局、その他） ・非アルコール性脂肪性肝疾患治療の北米市場：主要企業・種類別/用途別市場規模 ・非アルコール性脂肪性肝疾患治療のヨーロッパ市場：主要企業・種類別/用途別市場規模 ・非アルコール性脂肪性肝疾患治療の中国市場：主要企業・種類別/用途別市場規模 ・非アルコール性脂肪性肝疾患治療の日本国内市場：主要企業・種類別/用途別市場規模 ・非アルコール性脂肪性肝疾患治療の東南アジア市場：主要企業・種類別/用途別市場規模 ・非アルコール性脂肪性肝疾患治療のインド市場：主要企業・種類別/用途別市場規模 ・非アルコール性脂肪性肝疾患治療の中南米市場：主要企業・種類別/用途別市場規模 ・主要企業のプロフィール （Pfizer、Roche、Daewoong、Cardax、Merck、Novartis、Gilead Sciences、AstraZeneca、Limerick BioPharma、GW Pharmaceuticals、Allergan、Takeda Pharmaceutical） ・非アルコール性脂肪性肝疾患治療の市場規模予測2019-2025 （種類別、用途別、地域別市場予測） ・アナリストの観点・結論 ... |
Fatty liver disease refers to the accumulation of fat (triglycerides,) in the liver. The liver cell contains fats, but the accumulation of excess fat can be a cause of concern and can lead to liver inflammation known as steatohepatitis. The fatty liver can be caused by alcohol as well as can be non-alcohol. Steatohepatitis can cause liver cirrhosis (fibrosis, scarring, and hardening of the liver). The cause of non-alcoholic fatty liver disease (NAFLD) is unknown. The nonalcoholic fatty liver disease (NAFLD) is one of the most common diseases in the United States. The prevalence of nonalcoholic fatty liver disease (NAFLD) is rising due to rise in prevalence of diabetes and obesity. According to National Health and Nutrition Examination survey, about 20-30% of the general population in the western world suffer from nonalcoholic fatty liver disease (NAFLD). The common symptoms include fatigue, weakness, weight loss and others. The diagnosis of NAFLD requires the combination of different tests such as blood test, ultrasound, CT scan, MRI scan, and liver biopsy. The two types of Nonalcoholic fatty liver disease (NAFLD) includes simple fatty liver and Nonalcoholic Steatohepatitis (NASH). The simple fatty liver is a type of nonalcoholic fatty liver (NAFL), in which fat is deposited, but no inflammation or liver damage is observed. NASH is the inflammation of the liver due to excess fat deposit and can lead to liver damage and disease.North America is estimated to lead the global nonalcoholic fatty liver disease treatment market due to increase in prevalence of diabetes and cardiovascular diseases in United States. Large number of manufacturers exist in the market, with large number of customer base. Asia Pacific market is also projected to experience high growth in the near future owing to factors such as, increase in healthcare expenditure, rising standard of living, lifestyle changes- attributed to better healthcare and awareness of the cost-effective treatment process with government grants and funding for acceleration in research and development activities.
In 2018, the global Non Alcoholic Fatty Liver Disease Treatment market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.
This report focuses on the global Non Alcoholic Fatty Liver Disease Treatment status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Non Alcoholic Fatty Liver Disease Treatment development in United States, Europe and China.
The key players covered in this study
Pfizer
Roche
Daewoong
Cardax
Merck
Novartis
Gilead Sciences
AstraZeneca
Limerick BioPharma
GW Pharmaceuticals
Allergan
Takeda Pharmaceutical
Market segment by Type, the product can be split into
Antioxidants
Thiazolidinedione
Biguanides
Lipid lowering Agents
FXR Receptor Agonist
Others
Market segment by Application, split into
Hospital Pharmacy
Retail Pharmacy
Drug Stores
Online Pharmacy
Others
Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central & South America
The study objectives of this report are:
To analyze global Non Alcoholic Fatty Liver Disease Treatment status, future forecast, growth opportunity, key market and key players.
To present the Non Alcoholic Fatty Liver Disease Treatment development in United States, Europe and China.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.
In this study, the years considered to estimate the market size of Non Alcoholic Fatty Liver Disease Treatment are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.
Table of Contents
1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered
1.4 Market Analysis by Type
1.4.1 Global Non Alcoholic Fatty Liver Disease Treatment Market Size Growth Rate by Type (2014-2025)
1.4.2 Antioxidants
1.4.3 Thiazolidinedione
1.4.4 Biguanides
1.4.5 Lipid lowering Agents
1.4.6 FXR Receptor Agonist
1.4.7 Others
1.5 Market by Application
1.5.1 Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Application (2014-2025)
1.5.2 Hospital Pharmacy
1.5.3 Retail Pharmacy
1.5.4 Drug Stores
1.5.5 Online Pharmacy
1.5.6 Others
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Non Alcoholic Fatty Liver Disease Treatment Market Size
2.2 Non Alcoholic Fatty Liver Disease Treatment Growth Trends by Regions
2.2.1 Non Alcoholic Fatty Liver Disease Treatment Market Size by Regions (2014-2025)
2.2.2 Non Alcoholic Fatty Liver Disease Treatment Market Share by Regions (2014-2019)
2.3 Industry Trends
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Opportunities
3 Market Share by Key Players
3.1 Non Alcoholic Fatty Liver Disease Treatment Market Size by Manufacturers
3.1.1 Global Non Alcoholic Fatty Liver Disease Treatment Revenue by Manufacturers (2014-2019)
3.1.2 Global Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Manufacturers (2014-2019)
3.1.3 Global Non Alcoholic Fatty Liver Disease Treatment Market Concentration Ratio (CR5 and HHI)
3.2 Non Alcoholic Fatty Liver Disease Treatment Key Players Head office and Area Served
3.3 Key Players Non Alcoholic Fatty Liver Disease Treatment Product/Solution/Service
3.4 Date of Enter into Non Alcoholic Fatty Liver Disease Treatment Market
3.5 Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type and Application
4.1 Global Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2014-2019)
4.2 Global Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2014-2019)
5 United States
5.1 United States Non Alcoholic Fatty Liver Disease Treatment Market Size (2014-2019)
5.2 Non Alcoholic Fatty Liver Disease Treatment Key Players in United States
5.3 United States Non Alcoholic Fatty Liver Disease Treatment Market Size by Type
5.4 United States Non Alcoholic Fatty Liver Disease Treatment Market Size by Application
6 Europe
6.1 Europe Non Alcoholic Fatty Liver Disease Treatment Market Size (2014-2019)
6.2 Non Alcoholic Fatty Liver Disease Treatment Key Players in Europe
6.3 Europe Non Alcoholic Fatty Liver Disease Treatment Market Size by Type
6.4 Europe Non Alcoholic Fatty Liver Disease Treatment Market Size by Application
7 China
7.1 China Non Alcoholic Fatty Liver Disease Treatment Market Size (2014-2019)
7.2 Non Alcoholic Fatty Liver Disease Treatment Key Players in China
7.3 China Non Alcoholic Fatty Liver Disease Treatment Market Size by Type
7.4 China Non Alcoholic Fatty Liver Disease Treatment Market Size by Application
8 Japan
8.1 Japan Non Alcoholic Fatty Liver Disease Treatment Market Size (2014-2019)
8.2 Non Alcoholic Fatty Liver Disease Treatment Key Players in Japan
8.3 Japan Non Alcoholic Fatty Liver Disease Treatment Market Size by Type
8.4 Japan Non Alcoholic Fatty Liver Disease Treatment Market Size by Application
9 Southeast Asia
9.1 Southeast Asia Non Alcoholic Fatty Liver Disease Treatment Market Size (2014-2019)
9.2 Non Alcoholic Fatty Liver Disease Treatment Key Players in Southeast Asia
9.3 Southeast Asia Non Alcoholic Fatty Liver Disease Treatment Market Size by Type
9.4 Southeast Asia Non Alcoholic Fatty Liver Disease Treatment Market Size by Application
10 India
10.1 India Non Alcoholic Fatty Liver Disease Treatment Market Size (2014-2019)
10.2 Non Alcoholic Fatty Liver Disease Treatment Key Players in India
10.3 India Non Alcoholic Fatty Liver Disease Treatment Market Size by Type
10.4 India Non Alcoholic Fatty Liver Disease Treatment Market Size by Application
11 Central & South America
11.1 Central & South America Non Alcoholic Fatty Liver Disease Treatment Market Size (2014-2019)
11.2 Non Alcoholic Fatty Liver Disease Treatment Key Players in Central & South America
11.3 Central & South America Non Alcoholic Fatty Liver Disease Treatment Market Size by Type
11.4 Central & South America Non Alcoholic Fatty Liver Disease Treatment Market Size by Application
12 International Players Profiles
12.1 Pfizer
12.1.1 Pfizer Company Details
12.1.2 Company Description and Business Overview
12.1.3 Non Alcoholic Fatty Liver Disease Treatment Introduction
12.1.4 Pfizer Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2014-2019)
12.1.5 Pfizer Recent Development
12.2 Roche
12.2.1 Roche Company Details
12.2.2 Company Description and Business Overview
12.2.3 Non Alcoholic Fatty Liver Disease Treatment Introduction
12.2.4 Roche Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2014-2019)
12.2.5 Roche Recent Development
12.3 Daewoong
12.3.1 Daewoong Company Details
12.3.2 Company Description and Business Overview
12.3.3 Non Alcoholic Fatty Liver Disease Treatment Introduction
12.3.4 Daewoong Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2014-2019)
12.3.5 Daewoong Recent Development
12.4 Cardax
12.4.1 Cardax Company Details
12.4.2 Company Description and Business Overview
12.4.3 Non Alcoholic Fatty Liver Disease Treatment Introduction
12.4.4 Cardax Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2014-2019)
12.4.5 Cardax Recent Development
12.5 Merck
12.5.1 Merck Company Details
12.5.2 Company Description and Business Overview
12.5.3 Non Alcoholic Fatty Liver Disease Treatment Introduction
12.5.4 Merck Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2014-2019)
12.5.5 Merck Recent Development
12.6 Novartis
12.6.1 Novartis Company Details
12.6.2 Company Description and Business Overview
12.6.3 Non Alcoholic Fatty Liver Disease Treatment Introduction
12.6.4 Novartis Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2014-2019)
12.6.5 Novartis Recent Development
12.7 Gilead Sciences
12.7.1 Gilead Sciences Company Details
12.7.2 Company Description and Business Overview
12.7.3 Non Alcoholic Fatty Liver Disease Treatment Introduction
12.7.4 Gilead Sciences Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2014-2019)
12.7.5 Gilead Sciences Recent Development
12.8 AstraZeneca
12.8.1 AstraZeneca Company Details
12.8.2 Company Description and Business Overview
12.8.3 Non Alcoholic Fatty Liver Disease Treatment Introduction
12.8.4 AstraZeneca Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2014-2019)
12.8.5 AstraZeneca Recent Development
12.9 Limerick BioPharma
12.9.1 Limerick BioPharma Company Details
12.9.2 Company Description and Business Overview
12.9.3 Non Alcoholic Fatty Liver Disease Treatment Introduction
12.9.4 Limerick BioPharma Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2014-2019)
12.9.5 Limerick BioPharma Recent Development
12.10 GW Pharmaceuticals
12.10.1 GW Pharmaceuticals Company Details
12.10.2 Company Description and Business Overview
12.10.3 Non Alcoholic Fatty Liver Disease Treatment Introduction
12.10.4 GW Pharmaceuticals Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2014-2019)
12.10.5 GW Pharmaceuticals Recent Development
12.11 Allergan
12.12 Takeda Pharmaceutical
13 Market Forecast 2019-2025
13.1 Market Size Forecast by Regions
13.2 United States
13.3 Europe
13.4 China
13.5 Japan
13.6 Southeast Asia
13.7 India
13.8 Central & South America
13.9 Market Size Forecast by Product (2019-2025)
13.10 Market Size Forecast by Application (2019-2025)
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
12.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Disclaimer
15.3 Author Details
Table Non Alcoholic Fatty Liver Disease Treatment Key Market Segments
Table Key Players Non Alcoholic Fatty Liver Disease Treatment Covered
Table Global Non Alcoholic Fatty Liver Disease Treatment Market Size Growth Rate by Type 2014-2025 (Million US$)
Figure Global Non Alcoholic Fatty Liver Disease Treatment Market Size Market Share by Type 2014-2025
Figure Antioxidants Figures
Table Key Players of Antioxidants
Figure Thiazolidinedione Figures
Table Key Players of Thiazolidinedione
Figure Biguanides Figures
Table Key Players of Biguanides
Figure Lipid lowering Agents Figures
Table Key Players of Lipid lowering Agents
Figure FXR Receptor Agonist Figures
Table Key Players of FXR Receptor Agonist
Figure Others Figures
Table Key Players of Others
Table Global Non Alcoholic Fatty Liver Disease Treatment Market Size Growth by Application 2014-2025 (Million US$)
Figure Hospital Pharmacy Case Studies
Figure Retail Pharmacy Case Studies
Figure Drug Stores Case Studies
Figure Online Pharmacy Case Studies
Figure Others Case Studies
Figure Non Alcoholic Fatty Liver Disease Treatment Report Years Considered
Table Global Non Alcoholic Fatty Liver Disease Treatment Market Size 2014-2025 (Million US$)
Figure Global Non Alcoholic Fatty Liver Disease Treatment Market Size and Growth Rate 2014-2025 (Million US$)
Table Global Non Alcoholic Fatty Liver Disease Treatment Market Size by Regions 2014-2025 (Million US$)
Table Global Non Alcoholic Fatty Liver Disease Treatment Market Size by Regions 2014-2019 (Million US$)
Table Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Regions 2014-2019
Figure Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Regions 2014-2019
Figure Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Regions 2019
Table Market Top Trends
Table Global Non Alcoholic Fatty Liver Disease Treatment Revenue by Manufacturers (2014-2019) (Million US$)
Table Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Manufacturers (2014-2019)
Figure Global Non Alcoholic Fatty Liver Disease Treatment Market Share by Manufacturers in 2018
Table Global Non Alcoholic Fatty Liver Disease Treatment Manufacturers Market Concentration Ratio (CR5 and HHI)
Table Key Players Head office and Area Served
Table Key Players Non Alcoholic Fatty Liver Disease Treatment Product/Solution/Service
Table Date of Enter into Non Alcoholic Fatty Liver Disease Treatment Market
Table Mergers & Acquisitions, Expansion Plans
Table Global Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2014-2019) (Million US$)
Table Global Non Alcoholic Fatty Liver Disease Treatment Market Size Share by Type (2014-2019)
Figure Global Non Alcoholic Fatty Liver Disease Treatment Market Size Market Share by Type (2014-2019)
Table Global Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2014-2019) (Million US$)
Table Global Non Alcoholic Fatty Liver Disease Treatment Market Size Share by Application (2014-2019)
Figure Global Non Alcoholic Fatty Liver Disease Treatment Market Size Market Share by Application (2014-2019)
Figure Global Non Alcoholic Fatty Liver Disease Treatment Revenue Market Share by Application in 2018
Figure United States Non Alcoholic Fatty Liver Disease Treatment Market Size 2014-2019 (Million US$)
Table United States Key Players Non Alcoholic Fatty Liver Disease Treatment Revenue (2018-2019) (Million US$)
Table United States Key Players Non Alcoholic Fatty Liver Disease Treatment Market Share (2018-2019)
Table United States Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2014-2019) (Million US$)
Table United States Non Alcoholic Fatty Liver Disease Treatment Market Share by Type (2014-2019)
Table United States Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2014-2019) (Million US$)
Table United States Non Alcoholic Fatty Liver Disease Treatment Market Share by Application (2014-2019)
Figure Europe Non Alcoholic Fatty Liver Disease Treatment Market Size 2014-2019 (Million US$)
Table Europe Key Players Non Alcoholic Fatty Liver Disease Treatment Revenue (2018-2019) (Million US$)
Table Europe Key Players Non Alcoholic Fatty Liver Disease Treatment Market Share (2018-2019)
Table Europe Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2014-2019) (Million US$)
Table Europe Non Alcoholic Fatty Liver Disease Treatment Market Share by Type (2014-2019)
Table Europe Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2014-2019) (Million US$)
Table Europe Non Alcoholic Fatty Liver Disease Treatment Market Share by Application (2014-2019)
Figure China Non Alcoholic Fatty Liver Disease Treatment Market Size 2014-2019 (Million US$)
Table China Key Players Non Alcoholic Fatty Liver Disease Treatment Revenue (2018-2019) (Million US$)
Table China Key Players Non Alcoholic Fatty Liver Disease Treatment Market Share (2018-2019)
Table China Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2014-20189) (Million US$)
Table China Non Alcoholic Fatty Liver Disease Treatment Market Share by Type (2014-2019)
Table China Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2014-2019) (Million US$)
Table China Non Alcoholic Fatty Liver Disease Treatment Market Share by Application (2014-2019)
Figure Japan Non Alcoholic Fatty Liver Disease Treatment Market Size 2014-2019 (Million US$)
Table Japan Key Players Non Alcoholic Fatty Liver Disease Treatment Revenue (2018-2019) (Million US$)
Table Japan Key Players Non Alcoholic Fatty Liver Disease Treatment Market Share (2018-2019)
Table Japan Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2014-2019) (Million US$)
Table Japan Non Alcoholic Fatty Liver Disease Treatment Market Share by Type (2014-2019)
Table Japan Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2014-2019) (Million US$)
Table Japan Non Alcoholic Fatty Liver Disease Treatment Market Share by Application (2014-2019)
Figure Southeast Asia Non Alcoholic Fatty Liver Disease Treatment Market Size 2014-2019 (Million US$)
Table Southeast Asia Key Players Non Alcoholic Fatty Liver Disease Treatment Revenue (2018-2019) (Million US$)
Table Southeast Asia Key Players Non Alcoholic Fatty Liver Disease Treatment Market Share (2018-2019)
Table Southeast Asia Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2014-2019) (Million US$)
Table Southeast Asia Non Alcoholic Fatty Liver Disease Treatment Market Share by Type (2014-2019)
Table Southeast Asia Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2014-2019) (Million US$)
Table Southeast Asia Non Alcoholic Fatty Liver Disease Treatment Market Share by Application (2014-2019)
Figure India Non Alcoholic Fatty Liver Disease Treatment Market Size 2014-2019 (Million US$)
Table India Key Players Non Alcoholic Fatty Liver Disease Treatment Revenue (2018-2019) (Million US$)
Table India Key Players Non Alcoholic Fatty Liver Disease Treatment Market Share (2018-2019)
Table India Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2014-2019) (Million US$)
Table India Non Alcoholic Fatty Liver Disease Treatment Market Share by Type (2014-2019)
Table India Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2014-2019) (Million US$)
Table India Non Alcoholic Fatty Liver Disease Treatment Market Share by Application (2014-2019)
Figure Central & South America Non Alcoholic Fatty Liver Disease Treatment Market Size 2014-2019 (Million US$)
Table Central & South America Key Players Non Alcoholic Fatty Liver Disease Treatment Revenue (2018-2019) (Million US$)
Table Central & South America Key Players Non Alcoholic Fatty Liver Disease Treatment Market Share (2018-2019)
Table Central & South America Non Alcoholic Fatty Liver Disease Treatment Market Size by Type (2014-2019) (Million US$)
Table Central & South America Non Alcoholic Fatty Liver Disease Treatment Market Share by Type (2014-2019)
Table Central & South America Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2014-2019) (Million US$)
Table Central & South America Non Alcoholic Fatty Liver Disease Treatment Market Share by Application (2014-2019)
Table Pfizer Company Details
Table Pfizer Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2014-2019) (Million US$)
Figure Pfizer Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2014-2019)
Table Pfizer Recent Development
Table Roche Company Details
Table Roche Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2014-2019)(Million US$)
Figure Roche Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2014-2019)
Table Roche Recent Development
Table Daewoong Company Details
Table Daewoong Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2014-2019)(Million US$)
Figure Daewoong Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2014-2019)
Table Daewoong Recent Development
Table Cardax Company Details
Table Cardax Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2014-2019)(Million US$)
Figure Cardax Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2014-2019)
Table Cardax Recent Development
Table Merck Company Details
Table Merck Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2014-2019)(Million US$)
Figure Merck Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2014-2019)
Table Merck Recent Development
Table Novartis Company Details
Table Novartis Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2014-2019)(Million US$)
Figure Novartis Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2014-2019)
Table Novartis Recent Development
Table Gilead Sciences Company Details
Table Gilead Sciences Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2014-2019)(Million US$)
Figure Gilead Sciences Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2014-2019)
Table Gilead Sciences Recent Development
Table AstraZeneca Company Details
Table AstraZeneca Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2014-2019)(Million US$)
Figure AstraZeneca Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2014-2019)
Table AstraZeneca Recent Development
Table Limerick BioPharma Company Details
Table Limerick BioPharma Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2014-2019)(Million US$)
Figure Limerick BioPharma Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2014-2019)
Table Limerick BioPharma Recent Development
Table GW Pharmaceuticals Company Details
Table GW Pharmaceuticals Revenue in Non Alcoholic Fatty Liver Disease Treatment Business (2014-2019)(Million US$)
Figure GW Pharmaceuticals Revenue Growth Rate in Non Alcoholic Fatty Liver Disease Treatment Business (2014-2019)
Table GW Pharmaceuticals Recent Development
Table Allergan Company Details
Table Takeda Pharmaceutical Company Details
Table Global Non Alcoholic Fatty Liver Disease Treatment Market Size by Regions (Million US$) 2019-2025
Figure Global Non Alcoholic Fatty Liver Disease Treatment Market Size Share by Regions (2019-2025)
Figure Global Non Alcoholic Fatty Liver Disease Treatment Market Size Share by Regions in 2025
Figure United States Non Alcoholic Fatty Liver Disease Treatment Market Size Forecast (2019-2025)(Million USD)
Figure Europe Non Alcoholic Fatty Liver Disease Treatment Market Size Forecast (2019-2025)(Million USD)
Figure China Non Alcoholic Fatty Liver Disease Treatment Market Size Forecast (2019-2025)(Million USD)
Figure Japan Non Alcoholic Fatty Liver Disease Treatment Market Size Forecast (2019-2025)(Million USD)
Figure Southeast Asia Non Alcoholic Fatty Liver Disease Treatment Market Size Forecast (2019-2025)(Million USD)
Figure India Non Alcoholic Fatty Liver Disease Treatment Market Size Forecast (2019-2025)(Million USD)
Figure Central & South America Non Alcoholic Fatty Liver Disease Treatment Market Size Forecast (2019-2025)(Million USD)
Table Global Non Alcoholic Fatty Liver Disease Treatment Market Size by Product (2019-2025) (Million US$)
Figure Global Non Alcoholic Fatty Liver Disease Treatment Market Size by Product (2019-2025)
Figure Global Non Alcoholic Fatty Liver Disease Treatment Market Size by Product in 2025
Table Global Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2019-2025) (Million US$)
Figure Global Non Alcoholic Fatty Liver Disease Treatment Market Size by Application (2019-2025)
Figure Global Non Alcoholic Fatty Liver Disease Treatment Market Size by Application in 2025
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
脂肪肝治療の世界市場：市場規模・現状・予測 Fatty liver disease is one of the most common liver dysfunction where the triglyceride fat accumulates in liver cells.The major risks associated with fatty liver disease are alcoholic cirrhosis, cardiovascular disorder, metabolic syndrome and biliary cirrhosis among others. In 2018, the global Fatty…- 非アルコール性脂肪性肝疾患治療薬の世界市場：市場規模・現状・予測 Nonalcoholic fatty liver disease (NAFLD) is a condition in which excessive fatty accumulation in the hepatocytes. There are two types of NAFLD, namely simple fatty liver and non-alcoholic steatohepatitis. In simple fatty liver, the fat in the liver is very less and there is no inflammation or liver …
- アルコール性肝炎治療薬の世界市場：市場規模・現状・予測 Alcoholic hepatitis is hepatitis (inflammation of the liver) due to excessive intake of alcohol. It is usually found in association with fatty liver, an early stage of alcoholic liver disease, and may contribute to the progression of fibrosis, leading to cirrhosis. The increasing consumption of alco…
- パーキンソン病治療の世界市場：市場規模・現状・予測 Parkinson’s disease (PD) is a chronic and progressive disease, considered an idiopathic form, and accounts for roughly 80% of the cases of Parkinsonism—neurological disorders that lead to movement problems. While the exact cause of Parkinson’s disease is unknown, it may include a number of factors s…
- クラッベ病治療の世界市場：市場規模・現状・予測 Krabbe disease (KD) (also known as globoid cell leukodystrophy or galactosylceramide lipidosis) is a rare and often fatal lysosomal storage disease that results in progressive damage to the nervous system. KD involves dysfunctional metabolism of sphingolipids and is inherited in an autosomal recessi…